A. Jaworek, M. Jaworek, Przemysław Hałubiec, R. Kurzawa, A. Wojas-Pelc
Introduction: Atopic dermatitis is chronic and recurrent inflammatory dermatosis characterized by the pres-ence of skin pruritus and dryness. The crucial factor determining the therapeutic success is adequate collabo-ration between patient and physician. Emollients are recommended medications to be applicated at any point of atopic dermatitis management. Aim: To assess the impact of preferences, beliefs and adherence of caregivers of children suffering from atopic dermatitis in the aspect of recommended emollient therapy and their relationship to the symptoms severity in children. Material and methods: This is a pilot study. The answers from anonymous questionnaires regarding preferences, beliefs and adherence in the aspect of emollient therapy were collected from 50 parents of children suffering from atopic dermatitis. Each caregiver self-evaluated the itch severity using a visual-analogue scale as well as the skin condition in child. Nominal variables were compared using the c 2 test or 2-sided Fischer test. For the comparison between groups the Mann-Whitney’s U test and the Kruskal-Wallis’ test were used. Results: The predominantly selected formulation of emollient was the bath liquid/emulsion. A number of 39 caregivers remarked the positive effect of the emollient on the condition of skin in a child. The highest ratio of respondents applicated emollients twice a day. The determining factor for the choose of the emollient was the severity of skin lesions. Caregivers who indicated improvement in assessed skin condition and itch in children more frequently preferred emollients in the formulation of cream and ointment. According to the opinion of most study participants the crucial element of emollient therapy was the regular use of emollients. Regular use of emollients was an important factor related to the improvement of the clinical condition. Conclusions: Preferences and beliefs of caregivers may possess a significant impact on adherence during emollient therapy for atopic dermatitis in children which affects the benefits from treatment. The partnership of a physician and caregiver of a child with atopic dermatitis is the foundation for developing an individualized therapy schedule.
{"title":"Emollient therapy in children with atopic dermatitis – a pilot study","authors":"A. Jaworek, M. Jaworek, Przemysław Hałubiec, R. Kurzawa, A. Wojas-Pelc","doi":"10.5114/PJA.2020.96131","DOIUrl":"https://doi.org/10.5114/PJA.2020.96131","url":null,"abstract":"Introduction: Atopic dermatitis is chronic and recurrent inflammatory dermatosis characterized by the pres-ence of skin pruritus and dryness. The crucial factor determining the therapeutic success is adequate collabo-ration between patient and physician. Emollients are recommended medications to be applicated at any point of atopic dermatitis management. Aim: To assess the impact of preferences, beliefs and adherence of caregivers of children suffering from atopic dermatitis in the aspect of recommended emollient therapy and their relationship to the symptoms severity in children. Material and methods: This is a pilot study. The answers from anonymous questionnaires regarding preferences, beliefs and adherence in the aspect of emollient therapy were collected from 50 parents of children suffering from atopic dermatitis. Each caregiver self-evaluated the itch severity using a visual-analogue scale as well as the skin condition in child. Nominal variables were compared using the c 2 test or 2-sided Fischer test. For the comparison between groups the Mann-Whitney’s U test and the Kruskal-Wallis’ test were used. Results: The predominantly selected formulation of emollient was the bath liquid/emulsion. A number of 39 caregivers remarked the positive effect of the emollient on the condition of skin in a child. The highest ratio of respondents applicated emollients twice a day. The determining factor for the choose of the emollient was the severity of skin lesions. Caregivers who indicated improvement in assessed skin condition and itch in children more frequently preferred emollients in the formulation of cream and ointment. According to the opinion of most study participants the crucial element of emollient therapy was the regular use of emollients. Regular use of emollients was an important factor related to the improvement of the clinical condition. Conclusions: Preferences and beliefs of caregivers may possess a significant impact on adherence during emollient therapy for atopic dermatitis in children which affects the benefits from treatment. The partnership of a physician and caregiver of a child with atopic dermatitis is the foundation for developing an individualized therapy schedule.","PeriodicalId":7469,"journal":{"name":"Alergologia Polska - Polish Journal of Allergology","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70478277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
B. Rogala, M. Kupczyk, G. Bochenek, P. Śliwiński, M. Moniuszko, J. Glück, R. Dobek, M. Kulus
Biological therapy is the breakthrough in the management of spectrum of various diseases It also concerns asthma therapy The data regarding the role of biologics in the treatment strategy of severe asthma are presented The overview on how mediators of type 2 inflammation drives the pathology of the disease is given It justifies the biological treatment options approved The development of treatment strategy targeting non-type 2 inflammation is also highlighted The data regarding the risk and safety of biologics are discussed Document includes the featured rules of the classification of patients with severe asthma to this reliable and efficient therapy The outlook how to perceive the safety of biologics in the time of COVID-19 epidemic is also given
{"title":"Biological therapy of asthma – position statement of Polish Allergology Society (PTA) and Polish Society of Lung Diseases (PTChP)","authors":"B. Rogala, M. Kupczyk, G. Bochenek, P. Śliwiński, M. Moniuszko, J. Glück, R. Dobek, M. Kulus","doi":"10.5114/pja.2020.96664","DOIUrl":"https://doi.org/10.5114/pja.2020.96664","url":null,"abstract":"Biological therapy is the breakthrough in the management of spectrum of various diseases It also concerns asthma therapy The data regarding the role of biologics in the treatment strategy of severe asthma are presented The overview on how mediators of type 2 inflammation drives the pathology of the disease is given It justifies the biological treatment options approved The development of treatment strategy targeting non-type 2 inflammation is also highlighted The data regarding the risk and safety of biologics are discussed Document includes the featured rules of the classification of patients with severe asthma to this reliable and efficient therapy The outlook how to perceive the safety of biologics in the time of COVID-19 epidemic is also given","PeriodicalId":7469,"journal":{"name":"Alergologia Polska - Polish Journal of Allergology","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5114/pja.2020.96664","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70478317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Article offers analysis of main aspects of SARS-CoV-2/COVID-19 vaccination (severe acute respiratory syndrome coronavirus 2/COVID-19-Coronavirus Disease 2019) Optimal vaccine should protect not only against disease COVID-19 (symptoms), but also against SARS-CoV-2 infection (spreading disease) However, this kind of vaccine – showing highest safety level is extremely difficult to get Several additional SARS-CoV-2/COVID-19 vaccination issues were addressed in article For example: serological passports, herd immunity, clinical trials, and role of antibodies and T cells crossreactivities Article discusses some issues related to vaccination responsibilities
{"title":"Vaccine against COVID-19 or against SARS-CoV-2 infection?","authors":"P. Rieske","doi":"10.5114/pja.2020.97913","DOIUrl":"https://doi.org/10.5114/pja.2020.97913","url":null,"abstract":"Article offers analysis of main aspects of SARS-CoV-2/COVID-19 vaccination (severe acute respiratory syndrome coronavirus 2/COVID-19-Coronavirus Disease 2019) Optimal vaccine should protect not only against disease COVID-19 (symptoms), but also against SARS-CoV-2 infection (spreading disease) However, this kind of vaccine – showing highest safety level is extremely difficult to get Several additional SARS-CoV-2/COVID-19 vaccination issues were addressed in article For example: serological passports, herd immunity, clinical trials, and role of antibodies and T cells crossreactivities Article discusses some issues related to vaccination responsibilities","PeriodicalId":7469,"journal":{"name":"Alergologia Polska - Polish Journal of Allergology","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5114/pja.2020.97913","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70478380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Kowalski, Z. Bartuzi, A. Bręborowicz, E. Cichocka-Jarosz, M. Czarnecka-Operacz, J. Kruszewski, M. Kulus, M. Kupczyk, M. Moniuszko, M. Niedoszytko, M. Nittner-Marszalska, R. Nowicki, B. Rogala, M. Chałubiński
The Polish Allergology Society is one of the first to convene a panel of experts, who on March 30, 2020 presented a position on the management of patients with asthma and allergic diseases during the SARS-CoV-2 pandemic Most of the recommendations and opinions presented in this position remain valid until now However, the dynamically changing epidemiological situation associated with SARS-CoV-2 infection poses new challenges for physicians in the care of asthma and allergic diseases Numerous published clinical observations and studies provide new information on asthma and allergic diseases in relation to the COVID-19 pandemic The current document contains new recommendations in line with available knowledge and taking into ac-count the views of other national and international organizations and societies
{"title":"Position statement of expert panel of the Polish Allergology Sociey \u0000on the management of patients with bronchial asthma and allergic diseases during SARS-Cov-2 pandemics. Update 1.06.2020","authors":"M. Kowalski, Z. Bartuzi, A. Bręborowicz, E. Cichocka-Jarosz, M. Czarnecka-Operacz, J. Kruszewski, M. Kulus, M. Kupczyk, M. Moniuszko, M. Niedoszytko, M. Nittner-Marszalska, R. Nowicki, B. Rogala, M. Chałubiński","doi":"10.5114/pja.2020.99242","DOIUrl":"https://doi.org/10.5114/pja.2020.99242","url":null,"abstract":"The Polish Allergology Society is one of the first to convene a panel of experts, who on March 30, 2020 presented a position on the management of patients with asthma and allergic diseases during the SARS-CoV-2 pandemic Most of the recommendations and opinions presented in this position remain valid until now However, the dynamically changing epidemiological situation associated with SARS-CoV-2 infection poses new challenges for physicians in the care of asthma and allergic diseases Numerous published clinical observations and studies provide new information on asthma and allergic diseases in relation to the COVID-19 pandemic The current document contains new recommendations in line with available knowledge and taking into ac-count the views of other national and international organizations and societies","PeriodicalId":7469,"journal":{"name":"Alergologia Polska - Polish Journal of Allergology","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70478447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Skin prick test and patient informed consent","authors":"R. Pawliczak","doi":"10.5114/pja.2020.93831","DOIUrl":"https://doi.org/10.5114/pja.2020.93831","url":null,"abstract":"","PeriodicalId":7469,"journal":{"name":"Alergologia Polska - Polish Journal of Allergology","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5114/pja.2020.93831","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70477675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
In this article the authors analyze in detail the clinical role of immunoglobulins E and eosinophils in the etiology and pathogenesis of asthma, and their impact on the course of asthma. They discuss problems related to the treatment of severe bronchial asthma and new therapeutic options. They recall the positions of experts on the criteria for qualifying for biological therapies and discuss the order of drug use, especially in the group of patients presenting simultaneously the phenotype of allergic and eosinophilic asthma.
{"title":"Severe uncontrolled allergic eosinophilic asthma – looking for the best therapeutic option","authors":"I. Kupryś-Lipińska, P. Kuna","doi":"10.5114/pja.2020.101997","DOIUrl":"https://doi.org/10.5114/pja.2020.101997","url":null,"abstract":"In this article the authors analyze in detail the clinical role of immunoglobulins E and eosinophils in the etiology and pathogenesis of asthma, and their impact on the course of asthma. They discuss problems related to the treatment of severe bronchial asthma and new therapeutic options. They recall the positions of experts on the criteria for qualifying for biological therapies and discuss the order of drug use, especially in the group of patients presenting simultaneously the phenotype of allergic and eosinophilic asthma.","PeriodicalId":7469,"journal":{"name":"Alergologia Polska - Polish Journal of Allergology","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70477764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Z. Brzoza, Z. Bartuzi, M. Czarnecka-Operacz, K. Jahnz-Różyk, M. Kulus, J. Narbutt
{"title":"Expert group commentary on the international recommendation for management of urticaria: The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria [Allergy 2018; 73: 1393-1414]","authors":"Z. Brzoza, Z. Bartuzi, M. Czarnecka-Operacz, K. Jahnz-Różyk, M. Kulus, J. Narbutt","doi":"10.5114/pja.2020.93828","DOIUrl":"https://doi.org/10.5114/pja.2020.93828","url":null,"abstract":"","PeriodicalId":7469,"journal":{"name":"Alergologia Polska - Polish Journal of Allergology","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5114/pja.2020.93828","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70478001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
There is a dispute over whether COVID-19 is more deadly than the flu Disease mortality does not have to be a parameter that correctly describes the threat Sometimes population mortality does it better However this parameter can be calculated after all and does not help to prevent spread of new disease such as COVID-19 Unfortunately, the IFR for influenza is difficult to calculate Nevertheless, this study makes such an attempt for the USA This was possible in the case of the USA because it is a country that monitors both diseases relatively well According to these data, the estimated IFR (infection fatality rate) for COVID-19 was approximately 15 times higher than for influenza, whereas CFR (case fatality rate) was approximately 60 times for COVID-19 than for flu
{"title":"Estimated COVID-19 IFR was dozen times higher than flu IFR, whereas COVID-19 CFR was several dozen times higher than flu CFR in USA","authors":"P. Rieske","doi":"10.5114/pja.2020.102088","DOIUrl":"https://doi.org/10.5114/pja.2020.102088","url":null,"abstract":"There is a dispute over whether COVID-19 is more deadly than the flu Disease mortality does not have to be a parameter that correctly describes the threat Sometimes population mortality does it better However this parameter can be calculated after all and does not help to prevent spread of new disease such as COVID-19 Unfortunately, the IFR for influenza is difficult to calculate Nevertheless, this study makes such an attempt for the USA This was possible in the case of the USA because it is a country that monitors both diseases relatively well According to these data, the estimated IFR (infection fatality rate) for COVID-19 was approximately 15 times higher than for influenza, whereas CFR (case fatality rate) was approximately 60 times for COVID-19 than for flu","PeriodicalId":7469,"journal":{"name":"Alergologia Polska - Polish Journal of Allergology","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70477782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Adverse post-food reactions can manifest themselves both within a few minutes after contact with harmful food, as well as several or several dozen hours after eating potentially allergenic food protein. They can also cover a very wide spectrum of clinical symptoms, both mild or restricted, as well as very severe systemic re-
{"title":"The role of assay for allergen specific immunoglobulin G \u0000in the diagnosis of food allergy and intolerance","authors":"Z. Bartuzi, K. Lis, M. Żbikowska-Gotz","doi":"10.5114/pja.2020.96127","DOIUrl":"https://doi.org/10.5114/pja.2020.96127","url":null,"abstract":"Adverse post-food reactions can manifest themselves both within a few minutes after contact with harmful food, as well as several or several dozen hours after eating potentially allergenic food protein. They can also cover a very wide spectrum of clinical symptoms, both mild or restricted, as well as very severe systemic re-","PeriodicalId":7469,"journal":{"name":"Alergologia Polska - Polish Journal of Allergology","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5114/pja.2020.96127","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70477949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Allergic rhinitis and central nervous system disorders","authors":"G. Walkiewicz, Marta Sobolczyk, R. Pawliczak","doi":"10.5114/pja.2020.96128","DOIUrl":"https://doi.org/10.5114/pja.2020.96128","url":null,"abstract":"","PeriodicalId":7469,"journal":{"name":"Alergologia Polska - Polish Journal of Allergology","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5114/pja.2020.96128","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70478408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：